INVIVO THERAPEUTICS HOLDINGS CORP.

CAMBRIDGE, MA · CIK 0001292519 · Biotech · Public

Specialized clinical platforms for microbiome analysis, genomics testing, biomarker identification, peptide therapeutics, and vagus nerve modulation

invivo.health →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$9.3M
3 Form D · Oct 2022
48 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,000,000
Private capital raisedForm D · SEC$3,022,576
Private capital raisedForm D · SEC$6,249,999
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2132ProteoPrinceps, LLC——
2133Rebiotix Inc.—$29M
2134Mahzi Therapeutics Inc.—$27M
2135INVIVO THERAPEUTICS HOLDINGS CORP.—$9.3M
2136Richard Fisher——
2137PLEXYMER, INC.——
2138SGN, Inc.—$3.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 14 related persons
  • Richard ChristopherExecutive Officer
  • Peter CokerDirector · Executive Officer
  • Heather HamelExecutive Officer
  • Daniel MarshakDirector
  • C. MerrifieldDirector
  • Christina MorrisonDirector
  • George NolenDirector
  • Christi PedraDirector
  • Peter ReichardDirector · Executive Officer
  • Frank ReynoldsDirector · Executive Officer
  • Richard RobertsDirector
  • Robert RosenthalDirector
  • Adam SternDirector
  • Richard ToselliDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.